UNICYCIVE THERAPEUTICS, INC. Proceeds from Issuance of Other Long-term Debt
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Proceeds from Issuance of Other Long-term Debt of $1.10 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt · last filed 2023-03-31
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for the quarter ending 2021-09-30 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for the quarter ending 2021-06-30 was $88.00K.
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for the quarter ending 2021-03-31 was $1.01M.
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for fiscal 2021 was $1.10M, a 14.88% decline from fiscal 2020.
- UNICYCIVE THERAPEUTICS, INC. proceeds from issuance of other long-term debt for fiscal 2020 was $1.29M.
| Period end | Proceeds from Issuance of Other Long-term Debt 3 month | Proceeds from Issuance of Other Long-term Debt 6 month | Proceeds from Issuance of Other Long-term Debt 9 month | Proceeds from Issuance of Other Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $88.00K derived: sum of 3 quarters · filed 2023-03-31 | $1.10M 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $88.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.10M 10-Q · filed 2022-11-14 | $1.49M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.10M 10-Q · filed 2022-08-15 | $1.49M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-12 | $1.40M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.29M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $900.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |